Nanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic index

International Journal of Nanomedicine

Volumn 5, Issue 1, 2010, Pages 51-62

  Hu, Kefei ^a   Berenjian, Saideh ^a   Larsson, Rolf ^b   Gullbo, Joachim ^b   Nygren, Peter ^b   Lövgren, Tanja ^c   Morein, Bror ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

Anticancer drug; Apoptosis; Nanoparticle; Quillaja saponin

Indexed keywords

CHOLESTEROL; INTERLEUKIN 8; NANOPARTICLE; SAPONIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG FORMULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOMA CELL LINE; MONOCYTE; QUILLAJA; QUILLAJA SAPONARIA;

QUILLAJA; QUILLAJA SAPONARIA;

EID: 77951177859     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/ijn.s7879     Document Type: Article

References (25)

1. Nygren P, Larsson R. Overview of the clinical efficacy of investigational anticancer drugs. J Intern Med. 2003;253(1):46-75.
2. Kerwin SM. Soy saponins and the anticancer effects of soybeans and soy-based foods. Curr Med Chem Anticancer Agents. 2004;4(3): 263-272.
3. Rao AV, Sung MK. Saponins as anticarcinogens. J Nutr. 1995; 125(3 Suppl):717S-724S.
4. Tian F, Zhang X, Tong Y, et al. PE, a new sulfated saponin from sea cucumber, exhibits anti-angiogenic and anti-tumor activities in vitro and in vivo. Cancer Biol Ther. 2005;4(8):874-882.
5. Tin MM, Cho CH, Chan K, James AE, Ko JK. Astragalus saponins induce growth inhibition and apoptosis in human colon cancer cells and tumor xenograft. Carcinogenesis. 2007;28(6):1347-1355.
6. Hwang SJ, Cha JY, Park SG, et al. Diol- and triol-type ginseng saponins potentiate the apoptosis of NIH3T3 cells exposed to methyl methanesulfonate. Toxicol Appl Pharmacol. 2002;181(3):192-202.
7. Wang ZP. Saponins as Anticancer Agent. United States Patent 20050175623 A1; 2005.
8. Kensil CR, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol. 1991;146(2):431-437.
9. Kersten GF, Spiekstra A, Beuvery EC, Crommelin DJ. On the structure of immune-stimulating saponin-lipid complexes (iscoms). Biochim Biophys Acta. 1991;1062(2):165-171.
10. Ronnberg B, Fekadu M, Morein B. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix. Vaccine. 1995;13(14):1375-1382.
11. Morein B, Hu K, Lovgren K, D'Hondt E. New ISCOMs meet unsettled vaccine demands. In: Singh MA, editor. Vaccine Adjuvants and Delivery Systems. Hoboken, NJ: John Wiley & Sons, Inc.; 2007. p. 191-222.
12. Lovgren K, Morein B. The ISCOM: an antigen delivery system with built-in adjuvant. Mol Immunol. 1991;28(3):285-286.
13. Lovgren K, Morein B. The ISCOM™ Technology. Vaccin adjuvants: Preparation methods and research protocols. Methods Mol Med. 2000; 42:239-258.
14. Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. ISCOM, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature. 1984;308(5958):457-460.
15. Dalton W, Durie B, Alberts D, Gerlach J, Cress A. Characterization of a new drug-resistant human myeloma cell line that expresses p-glycoprotein. Cancer Res. 1986;46:5125-5130.
16. Bellamy W, Dalton W, Gleason M, Grogan T, Trent J. Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res. 1991;51:995-1002.
17. Botling J, Liminga G, Larsson R, Nygren P, Nilsson K. Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170 kDa p-glycoprotein. Int J Cancer. 1994;58: 269-274.
18. Danks M, Schmidt C, Cirtain M, Suttle D, Beck W. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry. 1988;27:8861-8869.
19. Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer. 1992;50:177-185.
20. Lovborg H, Nygren P, Larsson R. Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828. Mol Cancer Ther. 2004;3(5):521-526.
21. Hilf R, Goldenberg H, Michel I, Orlando RA, Archer FL. Enzymes, nucleic acids, and lipids in human breast cancer and normal breast tissue. Cancer Res. 1970;30(6):1874-1882.
22. Perkins RG, Kummerow FA. Major lipid classes in plasma membrane isolated from liver of rats fed a hepatocarcinogen. Biochim Biophys Acta. 1976;424(3):469-480.
23. Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME, Rovere-Querini P. HMGB1: guiding immunity from within. Trends Immunol. 2005;26(7): 381-387.
24. Wikman M, Friedman M, Pinitkiatisakul S, et al. General strategies for efficient adjuvant incorporation of recombinant subunit immunogens. Vaccine. 2005;23(17-18):2331-2335.
25. Hu KF, Lovgren-Bengtsson K, Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv Drug Deliv Rev. 2001; 51(1-3):149-159.